The use of targeted radionuclide therapy for the treatment of malignant melanoma in vivo

C. Joyce, M. Boyd, A. Sorensen, M. Tesson, J. W. Babich, R. J. Mairs

Research output: Contribution to journalConference Contribution

Abstract

This study investigates the potential of the noradrenaline analogue [131I]MIBG (metaiodobenzylguanidine) and the novel melanin binding benzamide [131I]
Solazed for melanoma therapy in vivo and in vitro.
LanguageEnglish
Pages110-110
Number of pages1
JournalMutagenesis
Volume27
Issue number1
DOIs
Publication statusPublished - Jan 2012
Event34th Annual Meeting of the United Kingdom Environmental Mutagen Society - Nottingham, United Kingdom
Duration: 29 Jun 20111 Jul 2011

Fingerprint

3-Iodobenzylguanidine
Melanins
Radioisotopes
Melanoma
Norepinephrine
Therapeutics
In Vitro Techniques
benzamide

Keywords

  • targeted radionuclide therapy
  • treatment
  • malignant melanoma
  • in vivo
  • in vitro
  • noradrenaline analogue
  • metaiodobenzylguanidine

Cite this

Joyce, C. ; Boyd, M. ; Sorensen, A. ; Tesson, M. ; Babich, J. W. ; Mairs, R. J. / The use of targeted radionuclide therapy for the treatment of malignant melanoma in vivo. In: Mutagenesis. 2012 ; Vol. 27, No. 1. pp. 110-110.
@article{5f792abb8b834062af2b4dc6ac8b2cec,
title = "The use of targeted radionuclide therapy for the treatment of malignant melanoma in vivo",
abstract = "This study investigates the potential of the noradrenaline analogue [131I]MIBG (metaiodobenzylguanidine) and the novel melanin binding benzamide [131I] Solazed for melanoma therapy in vivo and in vitro.",
keywords = "targeted radionuclide therapy, treatment, malignant melanoma , in vivo, in vitro, noradrenaline analogue , metaiodobenzylguanidine",
author = "C. Joyce and M. Boyd and A. Sorensen and M. Tesson and Babich, {J. W.} and Mairs, {R. J.}",
year = "2012",
month = "1",
doi = "10.1093/mutage/ger068",
language = "English",
volume = "27",
pages = "110--110",
journal = "Mutagenesis",
issn = "0267-8357",
number = "1",

}

The use of targeted radionuclide therapy for the treatment of malignant melanoma in vivo. / Joyce, C.; Boyd, M.; Sorensen, A.; Tesson, M.; Babich, J. W.; Mairs, R. J.

In: Mutagenesis, Vol. 27, No. 1, 01.2012, p. 110-110.

Research output: Contribution to journalConference Contribution

TY - JOUR

T1 - The use of targeted radionuclide therapy for the treatment of malignant melanoma in vivo

AU - Joyce, C.

AU - Boyd, M.

AU - Sorensen, A.

AU - Tesson, M.

AU - Babich, J. W.

AU - Mairs, R. J.

PY - 2012/1

Y1 - 2012/1

N2 - This study investigates the potential of the noradrenaline analogue [131I]MIBG (metaiodobenzylguanidine) and the novel melanin binding benzamide [131I] Solazed for melanoma therapy in vivo and in vitro.

AB - This study investigates the potential of the noradrenaline analogue [131I]MIBG (metaiodobenzylguanidine) and the novel melanin binding benzamide [131I] Solazed for melanoma therapy in vivo and in vitro.

KW - targeted radionuclide therapy

KW - treatment

KW - malignant melanoma

KW - in vivo

KW - in vitro

KW - noradrenaline analogue

KW - metaiodobenzylguanidine

U2 - 10.1093/mutage/ger068

DO - 10.1093/mutage/ger068

M3 - Conference Contribution

VL - 27

SP - 110

EP - 110

JO - Mutagenesis

T2 - Mutagenesis

JF - Mutagenesis

SN - 0267-8357

IS - 1

ER -